A Registry for Subjects With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

Trial Profile

A Registry for Subjects With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 18 May 2017 Planned number of patients changed from 2000 to 1637.
    • 18 May 2017 Planned End Date changed from 1 Nov 2022 to 1 May 2024.
    • 18 May 2017 Planned primary completion date changed from 1 Nov 2022 to 1 May 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top